Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
A vitamer () is any form in which some vitamin occurs. Each vitamer of a particular vitamin is a compound that performs the functions of that vitamin and prevents the symptoms of deficiency of the vitamin. Early research identified vitamins by their ability to cure vitamin-specific deficiency diseases. For example, vitamin B1 was first identified as a substance that prevented and treated beriberi. Subsequent nutrition research has revealed that all vitamers exhibit biological activity against their specific vitamin deficiency, although different vitamers exhibit different potencies against those diseases. A set of vitamers with related biological activity are grouped together by a general name, or generic descriptor, that refers to similar compounds with the same vitamin function. For example, vitamin A is the generic descriptor for the class of vitamin A vitamers which includes retinol, retinal, retinoic acid, and provitamin carotenoids such as beta-carotene, among others.
transfection The deliberate experimental introduction of exogenous nucleic acids into a cell or embryo. In the broadest sense the term may refer to any such transfer and is sometimes used interchangeably with transformation, though some applications restrict the usage of transfection to the introduction of naked or purified non-viral DNA or RNA into cultured eukaryotic cells (especially animal cells) resulting in the subsequent incorporation of the foreign DNA into the host genome or the non-hereditary modification of gene expression by the foreign RNA. As a contrast to both standard non-viral transformation and transduction, transfection has also occasionally been used to refer to the uptake of purified viral nucleic acids by bacteria or plant cells without the aid of a viral vector.
=== United Cup === Zverev has started his season every year since 2023 by participating in the United Cup. In 2023, Zverev and Team Germany were placed in Group C alongside the Czech Republic and the USA. Against the Czech Republic, he lost to Jiří Lehečka. The Czech Republic won the tie over Germany 3–2. Against the US, he lost to Taylor Fritz. The USA beat Germany 5–0. Germany failed to qualify for the knockout round and ended third in Group C. In 2024, Zverev returned to the United Cup in Sydney, Australia for the second consecutive year, leading Team Germany alongside Angelique Kerber. He won both of his singles matches in the round-robin stage, defeating Lorenzo Sonego of Italy and Adrian Mannarino of France both in three sets. He played both mixed doubles matches in both ties with Angelique Kerber, partnering for the first time since 2019, and won against Team Italy but not Team France. Despite this, Team Germany managed to qualify as the best runner-up team from all countries participating in Sydney, advancing to the quarterfinals against Greece. There, Zverev decisively won his singles match against Stefanos Tsitsipas and his mixed doubles match, partnering with doubles specialist Laura Siegemund, against Maria Sakkari and Petros Tsitsipas. In the semifinal tie against Australia, Zverev was defeated by Alex de Minaur in three sets, allowing the Australian to crack the top 10 after previously making top 10 wins against Taylor Fritz and Novak Djokovic earlier that week.
Liakhov, a vigorous, able, and reactionary officer firmly committed to upholding absolute monarchies whatever in Russia or Iran, transformed the Persian Cossack Brigade into a mounted para-military police force rather than as a combat force. Liakhov was close to the new Shah, Mohammed Ali, who ascended to the Peacock Throne in January 1907, and it was due to the shah's patronage that Liakhov transformed the Persian Cossack Brigade into the main bulwark of the Iranian state. In June 1908, Liakhov led the Cossack Brigade in bombarding the Majlis (Parliament) while being appointed military governor of Tehran as the shah attempted to do away with the constitution his father had been forced to grant in 1906 Reza Khan, who became the first Iranian to command the Cossack Brigade led the coup d'état in 1921 and in 1925 deposed the Qajars to found a new dynasty. After the outbreak of World War I in August 1914, Cossacks became a key component in the cavalry of the Imperial Russian Army. The mounted Cossacks made up 38 regiments, plus some infantry battalions and 52 horse artillery batteries. Initially, each Russian cavalry division included a regiment of Cossacks in addition to regular units of hussars, lancers, and dragoons. By 1916, the Cossacks' wartime strength had expanded to 160 regiments, plus 176 independent sotnias (squadrons) employed as detached units. The importance of cavalry in the frontlines faded after the opening phase of the war settled into a stalemate.
Sources: en.wikipedia.org
It is possible for an entire large sand pile to reach a point where it is stable, but the addition of a single grain causes large parts of it to collapse. The avalanche is a well-known problem with large piles of snow and ice crystals on steep slopes. In dry conditions, snow slopes act similarly to sandpiles. An entire mountainside of snow can suddenly slide due to the presence of a skier, or even a loud noise or vibration.
== G == GC-MS – Gas chromatography-mass spectrometry GDMS – Glow discharge mass spectrometry GDOS – Glow discharge optical spectroscopy GISAXS – Grazing incidence small angle X-ray scattering GIXD – Grazing incidence X-ray diffraction GIXR – Grazing incidence X-ray reflectivity GLC – Gas-liquid chromatography GPC – Gel permeation chromatography
Loratadine, sold under the brand name Claritin among others, is a medication used to treat allergies. This includes allergic rhinitis (hay fever) and hives. It is also available in drug combinations such as loratadine/pseudoephedrine, in which it is combined with pseudoephedrine, a nasal decongestant. It is taken orally. Common side effects include sleepiness, dry mouth, and headache. Serious side effects are rare and include allergic reactions, seizures, and liver problems. Use during pregnancy appears to be safe but has not been well studied. It is not recommended in children less than two years old. It is in the second-generation antihistamine family of medications. Loratadine was patented in 1980 and came to market in 1988. It is on the World Health Organization's List of Essential Medicines. Loratadine is available as a generic medication. In the United States, it is available over the counter. In 2023, it was the 105th most commonly prescribed medication in the United States, with more than 6 million prescriptions; and the combination with pseudoephedrine was the 300th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.
Sources: en.wikipedia.org
Carbon has the highest melting point of any element, and in carbon arc lamps it had been demonstrated to produce incandescence fairly close to that of sunlight. However, carbon has a tendency to sublimate before reaching its melting point depending on pressure, which led to rapid blackening of vacuumed bulbs. The first commercially successful light bulb filaments were made from carbonized paper or bamboo. Carbon filaments have a negative temperature coefficient of resistance—as they get hotter, their electrical resistance decreases. This made the lamp sensitive to fluctuations in the power supply, since a small increase of voltage would cause the filament to heat up, reducing its resistance and causing it to draw even more power and heat even further. Carbon filaments were "flashed" by heating in a hydrocarbon vapor (usually gasoline), to improve their strength and uniformity. Metallized or "graphitized" filaments were first heated to high temperature to transform them into graphite, which further strengthened and smoothed the filament. These filaments have a positive temperature coefficient, like a metallic conductor, which stabilized the lamps operating properties against minor variations in supply voltage. Metal filaments were tried in 1897 and started to displace carbon starting around 1904. Tungsten has the highest available melting point, but brittleness was an obstacle. By 1910, a process was developed by William D. Coolidge at General Electric for production of a ductile form of tungsten.
Mechanical properties, see Strength of materials Chemical properties, see Chemistry Electrical properties, see Electricity Thermal properties, see Thermodynamics Optical properties, see Optics and Photonics Magnetic properties, see Magnetism The properties of a material determine its usability and hence its engineering application.
Michael Laposata is an American pathologist, fatty acid biochemist and specialist in blood coagulation. He was chair of the Department of Pathology at the University of Texas Medical Branch (UTMB) in Galveston and previously directed clinical laboratories at Massachusetts General Hospital and Vanderbilt University.[1][2] He is known for developing diagnostic management teams to recommend the correct tests and provide expert driven, patient specific interpretations of test results. He is also well known for his work on bleeding disorders misdiagnosed as child abuse, and as a plaintiff in the 2024 lawsuit that overturned the U.S. Food and Drug Administration's rule on laboratory developed tests.[1][3][4] In 2026 he founded ExpertDx, Inc.
=== Pharmacodynamics === Deramciclane acts as an antagonist at the serotonin 5-HT2A receptor, as an inverse agonist at the serotonin 5-HT2C receptor, and as a GABA reuptake inhibitor, Some studies also show the drug to have moderate affinity to dopamine D2 receptors and low affinity to dopamine receptor D1. Activation of the serotonin 5-HT2A and 5-HT2C receptors has been implicated in anxiety and mood. Deramciclane does not affect CYP3A4 activity in metabolizing other drugs, but it is a weak inhibitor of CYP2D6.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.